Ligand Pharmaceuticals LGND Proceeds from financial royalty assets
Proceeds from financial royalty assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:ProceedsFromFinancialRoyaltyAssets.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's proceeds from financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's proceeds from financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported proceeds from financial royalty assets of $6.98M in Q1 2026.
- How has Ligand Pharmaceuticals's proceeds from financial royalty assets changed year-over-year?
- Ligand Pharmaceuticals's proceeds from financial royalty assets increased by 121.6% year-over-year, from $3.15M to $6.98M.
- What is the long-term trend for Ligand Pharmaceuticals's proceeds from financial royalty assets?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's proceeds from financial royalty assets has grown at a 381.4% compound annual growth rate (CAGR), from $92K to $10.26M.
- What does proceeds from financial royalty assets mean?
- Reflects cash inflows generated from the monetization or collection of royalty-based financial assets. This captures the realized value of the company's portfolio of licensed intellectual property. Higher proceeds indicate successful commercialization and performance of the underlying products within the company's royalty portfolio.